ACTINIUM PHARMACEUTICALS INC

NYSE: ATNM (Actinium Pharmaceuticals, Inc.)

Kemas kini terakhir: 23 Jun, 5:32PM

1.52

0.02 (1.33%)

Penutupan Terdahulu 1.50
Buka 1.48
Jumlah Dagangan 478,045
Purata Dagangan (3B) 649,979
Modal Pasaran 47,417,768
Harga / Jualan (P/S) 652.71
Harga / Buku (P/B) 1.75
Julat 52 Minggu
1.03 (-32%) — 8.64 (468%)
Tarikh Pendapatan 4 Aug 2025 - 8 Aug 2025
EPS Cair (TTM) -1.47
Jumlah Hutang/Ekuiti (D/E MRQ) 5.58%
Nisbah Semasa (MRQ) 9.35
Aliran Tunai Operasi (OCF TTM) -33.27 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -17.95 M
Pulangan Atas Aset (ROA TTM) -39.14%
Pulangan Atas Ekuiti (ROE TTM) -130.87%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Menurun Menurun
Biotechnology (Global) Menurun Menurun
Stok Actinium Pharmaceuticals, Inc. - -

AISkor Stockmoo

-0.5
Konsensus Penganalisis -2.0
Aktiviti Orang Dalam NA
Volatiliti Harga -2.0
Purata Bergerak Teknikal 2.5
Osilator Teknikal -0.5
Purata -0.50

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
ATNM 47 M - - 1.75
LCTX 231 M - - 2.95
CYBN 167 M - - 1.01
PLX 126 M - 31.60 2.61
ANRO 65 M - - 0.490
SER 59 M - 1.76 35.92

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple targets in oncology and hematology, including CD45, CD33, HER3, and other. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company is based in New York, New York.

Sektor Healthcare
Industri Biotechnology
% Dimiliki oleh Orang Dalam 1.79%
% Dimiliki oleh Institusi 29.96%

Pemilikan

Nama Tarikh Syer Dipegang
Los Angeles Capital Management Llc 31 Mar 2025 233,247
Creative Financial Designs Inc /Adv 31 Mar 2025 105,631

Tiada data dalam julat masa ini.

Tiada data dalam julat masa ini.

1.751.751.601.601.461.461.311.311.171.17Jun 24Jun 24Jun 25Jun 25Jun 26Jun 26Jun 27Jun 27Jun 30Jun 30Jul 1Jul 1Jul 2Jul 2Jul 3Jul 3

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
0.0400.0400.0200.0200.0000.000-0.020-0.020-0.040-0.040MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda